Cymalon

Summary of Product Characteristics Updated 25-Apr-2017 | Actavis UK Ltd

1. Name of the medicinal product

Cymalon Lemon flavour Granules for Oral Solution

2. Qualitative and quantitative composition

Each sachet of 6.76g of granules contain the following actives:

Citric Acid (anhydrous) EP

1063.00mg

Sodium Citrate dihydrate EP

2819.00mg

Sodium Carbonate EP

130.00mg

Sodium Bicarbonate EP

1200.00mg

Excipients: Each sachet contains 1.5g of sucrose.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Granules for Oral Solution.

4. Clinical particulars
4.1 Therapeutic indications

Cymalon Granules is indicated for the relief of symptoms due to cystitis in adult females only.

4.2 Posology and method of administration

Route of administration: Oral

Adults One sachet to be taken in water, three times a day over 48 hours.

Children Cymalon Granules is not recommended for children.

4.3 Contraindications

Cymalon Granules should not be taken in cases of pregnancy, heart disease, high blood pressure, any form of kidney disease or whenever a restricted salt intake is indicated.

4.4 Special warnings and precautions for use

Patients should be advised against repeated use. If symptoms persist 48 hours after treatment is completed you are advised to consult your doctor. Do not exceed the stated dose. Keep out of the reach of children.

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.

This medicinal product contains 136.5mmol (or 3.14g) sodium per maximum daily dose (3 sachets). To be taken into consideration by patients on a controlled sodium diet.

4.5 Interaction with other medicinal products and other forms of interaction

Sodium containing preparations should be avoided by patients on lithium because sodium is preferentially absorbed by the kidney resulting in increased lithium excretion and reduced plasma levels.

Urinary alkalinisers should not be used with hexamine because it is only effective in acid urine.

The effects of a number of drugs may be reduced or increased by the alkalinisination of the urine and reduction in gastric pH brought about by the active ingredients in the product.

4.6 Pregnancy and lactation

Do not use during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

None stated.

4.8 Undesirable effects

Sodium bicarbonate may cause flatulence.

Mild diuresis may occur.

4.9 Overdose

Excessive administration of sodium citrate may cause gastrointestinal discomfort and diarrhoea. Excessive doses of sodium salts may lead to sodium overloading and hyperosmolality. Excessive administration of bicarbonate may lead to hypokalaemia and metabolic alkalosis, especially in patients with impaired renal function. Treatment is symptomatic and consists of appropriate correction of fluid and electrolyte balance.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Sodium Bicarbonate increases the alkali reserve of the plasma and increases excretion of urine, which is rendered less acidic. Sodium Citrate is used to make the urine alkaline in the treatment of urinary tract infections. Citric acid increases the secretion of urine and renders it less acidic. It is also used in the preparation of effervescent granules to aid effervescence.

5.2 Pharmacokinetic properties

Cymalon Granules is administered in the form of a solution.

5.3 Preclinical safety data

Not applicable.

6. Pharmaceutical particulars
6.1 List of excipients

Castor Sugar EP

Saccharin Sodium BP

Flavour Lemon Natural (F309)

6.2 Incompatibilities

There are no known records of incompatibilities.

6.3 Shelf life

36 months

6.4 Special precautions for storage

Protect from moisture.

6.5 Nature and contents of container

Cymalon granules are packed into low density polythene, aluminium foil and paper (PPFP) laminate sachets, each containing 6.76g granules. These are further packed into cardboard cartons each containing 6 sachets.

6.6 Special precautions for disposal and other handling

Not applicable.

7. Marketing authorisation holder

Actavis Group PTC ehf

Reykjavíkurvegi 76-78

220 Hafnarfjordur

Iceland.

8. Marketing authorisation number(s)

PL 30306/0066

9. Date of first authorisation/renewal of the authorisation

22 July 2002

10. Date of revision of the text

28/05/12

11. Dosimetry

IF APPLICABLE

12. Instructions for preparation of radiopharmaceuticals

IF APPLICABLE

Company Contact Details
Actavis UK Ltd

www.accord-healthcare.co.uk

Address

Actavis UK Ltd, a subsidiary of Accord Healthcare Ltd, Whiddon Valley, Barnstaple, Devon, EX32 8NS, UK

Fax

+44 (0)1271 346 106

Medical Information e-mail

Medinfo@accord-healthcare.com

Telephone

+44 (0)1271 385 200

Medical Information Direct Line

+44 (0)1271 385 257